سعر إدوكساغريل 30 مجم 10 أقراص مغلفة 2026

Edoxaban 30 mg film-coated tablets (RAMEDA, Egypt) — oral factor Xa inhibitor.

• Reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation (do not use if CrCL > 95 mL/min per US label).Population: Adults with NVAF (CrCL constraints per label)DailyMed (NLM)
• Treatment of deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial parenteral anticoagulation.Population: AdultsDailyMed (NLM)

• Most common adverse reactions include bleeding and anemia; also rash and abnormal liver tests in VTE trials (US label).General active-ingredient information · DailyMed (NLM)

• Active pathological bleeding.International label, same formulation · DailyMed (NLM)

• Boxed warnings (US): reduced efficacy in NVAF if CrCL >95 mL/min; premature discontinuation increases ischemic risk; spinal/epidural hematoma risk with neuraxial procedures. Also bleeding risk; avoid in mechanical valves / moderate-severe mitral stenosis; not recommended in triple-positive APS.International label, same formulation · DailyMed (NLM)

• Anticoagulants, antiplatelets, thrombolytics, chronic NSAIDs, SSRIs/SNRIsMajorIncreased bleeding risk; avoid long-term combination with other anticoagulants.DailyMed (NLM)
• Rifampin (P-gp inducer)MajorAvoid concomitant use.DailyMed (NLM)

• Insufficient human data; anticoagulants increase fetal/neonatal bleeding risk; use only if benefit justifies risk.General active-ingredient information · DailyMed (NLM)
• Advise not to breastfeed during treatment (US Savaysa).General active-ingredient information · DailyMed (NLM)

• Edoxaban: Selectively inhibits factor Xa, reducing thrombin generation and thrombus formation.